Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE

Patrick Schöffski; Michaela Kubičková; Agnieszka Woźniak; Jean Yves Blay; Sandra J. Strauss; Silvia Stacchiotti; Tomasz Świtaj; Veit Bücklein; Michael Leahy; Antoîne Italiano; Nicolás Isambert; Maria Dêbiec‐Rychter; Raf Sciot; Che‐Jui Lee; Frank M. Speetjens; Axelle Nzokirantevye; Anouk Neven; Bernd Kasper

doi:10.1016/j.ejca.2021.07.016

Related publications

Article2020

Abstract 794: Molecular analysis of archival inflammatory myofibroblastic tumor tissue samples from EORTC 90101 “CREATE” and correlation with response to crizotinib

Che‐Jui Lee, Patrick Schöffski, Elodie Modave, Bram Boeckx, Diether Lambrechts, Maria Dêbiec‐Rychter, Raf Sciot, Jozef Šufliarský, Hans Gelderblom, Jean Yves Blay, Agnieszka Woźniak

Article2020

Abstract 3191: Detection of molecular drivers in inflammatory myofibroblastic tumor: study on archival tissue from EORTC 90101 “CREATE” phase II clinical trial

Agnieszka Woźniak, Che‐Jui Lee, Tom van Wezel, Jozef Šufliarský, Hans Gelderblom, Jean Yves Blay, Maria Dêbiec‐Rychter, Raf Sciot, Judith V.M.G. Bovée, Patrick Schöffski

Article2021

Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 “CREATE” Trial

Che‐Jui Lee, Elodie Modave, Bram Boeckx, Silvia Stacchiotti, Piotr Rutkowski, Jean Yves Blay, Maria Dêbiec‐Rychter, Raf Sciot, Diether Lambrechts, Agnieszka Woźniak, Patrick Schöffski

Article2021

1540P Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study

Margaret von Mehren, Michael C. Heinrich, Suzanne George, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, César Serrano, Robin L. Jones, Steven Attia, Gina Z. D’Amato, Ping Chi, Peter Reichardt, Julie Nicole Meade, V. Reichert, Kelvin Shi, Rodrigo Ruiz‐Soto, Jean Yves Blay

Preprint2023

Data from Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib

Che‐Jui Lee, Patrick Schöffski, Elodie Modave, Tom van Wezel, Bram Boeckx, Jozef Šufliarský, Hans Gelderblom, Jean Yves Blay, Maria Dêbiec‐Rychter, Raf Sciot, Judith V.M.G. Bovée, Diether Lambrechts, Agnieszka Woźniak